Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Danish Centre for Evaluation and Health Technology Assessment. Anti-Immunglobulin E (omalizumab) til behandling af allergisk astma hos voksne. [Anti-immunoglobulin E (omalizumab) for the treatment of allergic asthma in adults] Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). 2003 Authors' conclusions Several scientific studies have documented that treatment with omalizumab results in fewer and milder asthma exacerbations per person, and that fewer patients suffer asthma exacerbations. In addition, hospitalization time shortens and quality of life improves. Few side effects have been observed, although a few of these may be serious.
Omalizumab treatment will probably cost approx. USD 10–12,000 per year. Even when used solely in cases of severe asthma, it is unclear whether omalizumab can reduce the costs associated with hospitalization, emergency room visits and loss of production sufficiently to render the treatment cost effective. Indexing Status Subject indexing assigned by CRD MeSH Anti-Asthmatic Agents /therapeutic use; Antibodies, Monoclonal /therapeutic use; Asthma /drug therapy; Hypersensitivity /complications; Immunoglobulin E /blood Country of organisation Denmark English summary An English language summary is available. Address for correspondence National Board of Health, Islands Brygge 67, DK-2300 Copenhagen S, Denmark, Tel: +45 72 22 75 48, Fax: +45 72 22 74 03/ +45 72 22 74 11 Email: dacehta@sst.dk AccessionNumber 32005000560 Date bibliographic record published 20/08/2005 Date abstract record published 20/08/2005 |
